US7048906B2
(en)
*
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
US6861053B1
(en)
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
US6331311B1
(en)
*
|
1996-12-20 |
2001-12-18 |
Alza Corporation |
Injectable depot gel composition and method of preparing the composition
|
AU8530498A
(en)
|
1997-06-05 |
1998-12-21 |
Roland Bodmeier |
Multiphase system
|
US7745216B2
(en)
*
|
1999-02-10 |
2010-06-29 |
Curis, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
DK1189629T3
(en)
|
1999-02-10 |
2011-01-03 |
Curis Inc |
Peptide YY (PYY) for the treatment of glucose metabolism
|
JP2003501375A
(en)
*
|
1999-06-04 |
2003-01-14 |
アルザ・コーポレーション |
Implantable gel composition and method of manufacture
|
WO2001051024A2
(en)
|
2000-01-11 |
2001-07-19 |
Roland Bodmeier |
Implantation kit comprising a support phase and a solvent
|
US6524580B1
(en)
|
2000-02-15 |
2003-02-25 |
Allergan Sales, Inc. |
Method for treating thyroid disorders
|
US6358513B1
(en)
|
2000-02-15 |
2002-03-19 |
Allergan Sales, Inc. |
Method for treating Hashimoto's thyroiditis
|
US6773711B2
(en)
*
|
2000-02-15 |
2004-08-10 |
Allergan, Inc. |
Botulinum toxin therapy for Hashimoto's thyroiditis
|
US6649161B1
(en)
|
2000-02-22 |
2003-11-18 |
Allergan, Inc. |
Method for treating hypocalcemia
|
US20030211974A1
(en)
*
|
2000-03-21 |
2003-11-13 |
Brodbeck Kevin J. |
Gel composition and methods
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
AU2002230843B8
(en)
*
|
2000-12-14 |
2007-05-17 |
Amylin Pharmaceuticals, Llc |
Peptide YY and peptide YY agonists for treatment of metabolic disorders
|
DE60231862D1
(en)
*
|
2001-02-23 |
2009-05-20 |
Genentech Inc |
ERODABLE POLYMERS FOR INJECTION
|
ES2329346T3
(en)
*
|
2001-11-14 |
2009-11-25 |
Durect Corporation |
COMPOSITION OF INJECTABLE DEPOSIT.
|
US7122622B2
(en)
*
|
2002-04-16 |
2006-10-17 |
Biosynthema Inc. |
Peptide compounds having improved binding affinity to somatostatin receptors
|
AU2003243545A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Amylin Pharmaceuticals, Inc. |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
US7229966B2
(en)
*
|
2002-12-17 |
2007-06-12 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
EA008829B1
(en)
*
|
2002-12-17 |
2007-08-31 |
Нэстек Фармасьютикал Кампани Инк. |
Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
|
US7186692B2
(en)
|
2002-12-17 |
2007-03-06 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP5229768B2
(en)
|
2003-06-26 |
2013-07-03 |
シヴィダ・ユーエス・インコーポレイテッド |
In-situ gelled drug delivery system
|
CA2530113C
(en)
|
2003-06-26 |
2013-08-13 |
Control Delivery Systems, Inc. |
Bioerodible sustained release drug delivery systems
|
CN100428923C
(en)
*
|
2003-10-06 |
2008-10-29 |
株式会社资生堂 |
External use composition
|
JP5105578B2
(en)
|
2003-11-05 |
2012-12-26 |
サーコード バイオサイエンス インコーポレイテッド |
Cell adhesion modulator
|
TWI353250B
(en)
*
|
2003-12-16 |
2011-12-01 |
Ipsen Pharma Sas |
Glp-1 pharmaceutical compositions
|
CA2555894A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
GB0412866D0
(en)
*
|
2004-06-09 |
2004-07-14 |
Novartis Ag |
Organic compounds
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
US8318210B2
(en)
|
2005-02-28 |
2012-11-27 |
Neos Therapeutics, Lp |
Compositions and methods of making sustained release liquid formulations
|
CN101189249B
(en)
|
2005-04-01 |
2013-04-17 |
加利福尼亚大学董事会 |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
SI2444079T1
(en)
|
2005-05-17 |
2017-05-31 |
Sarcode Bioscience Inc. |
Compositions and Methods for Treatment of Eye Disorders
|
JP5095615B2
(en)
*
|
2005-06-27 |
2012-12-12 |
バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ |
Modified release of bupropion salt
|
EP1909771A1
(en)
*
|
2005-08-02 |
2008-04-16 |
Miv Therapeutics Inc. |
Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
|
KR20080066926A
(en)
*
|
2005-09-26 |
2008-07-17 |
호스피라 오스트레일리아 피티와이 리미티드 |
Fulvestrant formulation
|
US20070092553A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Pfab Lp |
Compositions and methods of making rapidly dissolving lonically masked formulations
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
US20070232671A1
(en)
*
|
2006-03-13 |
2007-10-04 |
Given Bruce D |
Methods and compositions for treatment of diastolic heart failure
|
WO2007106468A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Formulations of sitaxsentan sodium
|
AU2007225088B2
(en)
|
2006-03-13 |
2012-09-13 |
Kyorin Pharmaceutical Co., Ltd |
Aminoquinolones as GSK-3 inhibitors
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
PL2359808T3
(en)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotic delivery systems and piston assemblies
|
US7879846B2
(en)
|
2006-09-21 |
2011-02-01 |
Kyorin Pharmaceutical Co.., Ltd. |
Serine hydrolase inhibitors
|
DE602007013440D1
(en)
|
2006-10-19 |
2011-05-05 |
Auspex Pharmaceuticals Inc |
SUBSTITUTED INDOLE
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
CA2671766A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
DK2144604T3
(en)
|
2007-02-28 |
2011-10-17 |
Conatus Pharmaceuticals Inc |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
SI2125698T1
(en)
|
2007-03-15 |
2016-12-30 |
Auspex Pharmaceuticals, Inc. |
DEUTERATED d9-VENLAFAXINE
|
MX2009011123A
(en)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Suspension formulations of insulinotropic peptides and uses thereof.
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
JP2010529040A
(en)
*
|
2007-05-30 |
2010-08-26 |
ネオス・セラピューティクス・エルピー |
Control of drug release in suspensions of ionic resin systems
|
CA3089569C
(en)
|
2007-06-04 |
2023-12-05 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
MX2010000465A
(en)
*
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders.
|
CA2699151A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
MX2010002662A
(en)
|
2007-09-12 |
2010-04-09 |
Activx Biosciences Inc |
Spirocyclic aminoquinolones as gsk-3 inhibitors.
|
CA2958665C
(en)
|
2007-10-19 |
2021-03-02 |
Sarcode Bioscience Inc. |
Compositions and methods for treatment of diabetic retinopathy
|
ES2324009B1
(en)
*
|
2007-11-23 |
2010-05-21 |
Gp Pharm S.A. |
PHARMACEUTICAL COMPOSITION OF SUSTAINED RELEASE OF SOMATOSTATINE OR AN ANALOG OF HIS.
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
US9107815B2
(en)
|
2008-02-22 |
2015-08-18 |
Allergan, Inc. |
Sustained release poloxamer containing pharmaceutical compositions
|
MY161576A
(en)
|
2008-03-17 |
2017-04-28 |
Ambit Biosciences Corp |
Quinazoline derivatives as raf kinase modulators and methods of use thereof
|
US20090258069A1
(en)
*
|
2008-04-15 |
2009-10-15 |
John Burnier |
Delivery of LFA-1 antagonists to the gastrointestinal system
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
CA2724594A1
(en)
*
|
2008-05-20 |
2009-11-26 |
John R. Wetterau |
Niacin and nsaid combination therapy
|
JP2011522828A
(en)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
|
TW201004632A
(en)
|
2008-07-02 |
2010-02-01 |
Idenix Pharmaceuticals Inc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
LT2341905T
(en)
|
2008-09-04 |
2020-09-25 |
Amylin Pharmaceuticals, Llc |
Sustained release formulations using non-aqueous carriers
|
CN102307892A
(en)
|
2008-12-31 |
2012-01-04 |
西尼克斯公司 |
Derivatives of cyclosporin A
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
WO2010091234A2
(en)
|
2009-02-06 |
2010-08-12 |
The General Hospital Corporation |
Methods of treating vascular lesions
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
WO2010099379A1
(en)
|
2009-02-27 |
2010-09-02 |
Ambit Biosciences Corporation |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
WO2010101967A2
(en)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole hcv polymerase inhibitors
|
JP2012520314A
(en)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
Combination of indazolylaminopyrrolotriazine and taxane for cancer treatment
|
EP2406266B1
(en)
*
|
2009-03-11 |
2013-12-25 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
MX2011010105A
(en)
|
2009-03-27 |
2012-01-12 |
Pathway Therapeutics Inc |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy.
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
MX357611B
(en)
|
2009-04-22 |
2018-07-17 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists.
|
PE20120811A1
(en)
|
2009-04-22 |
2012-07-08 |
Axikin Pharmaceuticals Inc |
CCR3 ARYLSULFONAMIDE ANTAGONISTS
|
EP2421829B1
(en)
|
2009-04-22 |
2015-09-30 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
AR080945A1
(en)
|
2009-07-07 |
2012-05-23 |
Pathway Therapeutics Inc |
PIRIMIDINIL AND 1,3,5-TRIAZINIL BENZIMIDAZOLES AND ITS USE IN THERAPY AGAINST CANCER
|
HUE035519T2
(en)
|
2009-07-08 |
2018-05-02 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
BR112012003661A2
(en)
|
2009-08-19 |
2017-04-25 |
Ambit Biosciences Corp |
"Biaryl compounds and methods of use thereof."
|
NZ598686A
(en)
|
2009-09-28 |
2014-05-30 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
US8378105B2
(en)
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
US8470817B2
(en)
*
|
2009-10-26 |
2013-06-25 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
AR079528A1
(en)
|
2009-12-18 |
2012-02-01 |
Idenix Pharmaceuticals Inc |
5,5-FUSIONED ARYLENE OR HETEROARYLENE INHIBITORS OF HEPATITIS C VIRUS
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
CN102834409A
(en)
|
2009-12-30 |
2012-12-19 |
西尼克斯公司 |
Cyclosporine analogues
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011097525A1
(en)
|
2010-02-05 |
2011-08-11 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
SI2536706T1
(en)
|
2010-02-11 |
2017-10-30 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
AU2011223873B2
(en)
|
2010-03-02 |
2015-06-25 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
EP2547655B1
(en)
|
2010-03-17 |
2016-03-09 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide ccr3 antagonists
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
CA2801001A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
EP2585063A1
(en)
|
2010-06-01 |
2013-05-01 |
Biotheryx Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
MX2012014273A
(en)
|
2010-06-07 |
2013-03-22 |
Novomedix Llc |
Furanyl compounds and the use thereof.
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
EP3626253B8
(en)
|
2010-08-11 |
2022-04-20 |
Ironwood Pharmaceuticals, Inc. |
Stable formulations of linaclotide
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
EP2611502A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
WO2012030910A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
KR20130102060A
(en)
|
2010-09-01 |
2013-09-16 |
암비트 바이오사이언시즈 코포레이션 |
Quinazoline compounds and methods of use thereof
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
WO2012030894A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
WO2012030913A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
EP2611792B1
(en)
|
2010-09-01 |
2017-02-01 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
EP2611794A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
MX2013003954A
(en)
|
2010-10-11 |
2013-08-01 |
Axikin Pharmaceuticals Inc |
Salts of arylsulfonamide ccr3 antagonists.
|
EP2637669A4
(en)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
AU2011338530B2
(en)
|
2010-12-06 |
2017-06-15 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
CA2824197C
(en)
|
2011-01-10 |
2020-02-25 |
Michael Martin |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
JP2014503597A
(en)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
Pharmaceutical composition of cytidine analogue and method of use thereof
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
MX2013010217A
(en)
|
2011-03-11 |
2013-10-25 |
Celgene Corp |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2- 6-dione in treatment of immune-related and inflammatory diseases.
|
BR112013024907A2
(en)
|
2011-03-28 |
2016-12-20 |
Mei Pharma Inc |
compound, pharmaceutical composition, method for treating, preventing or attenuating one or more symptoms of a pi3k-mediated disorder, disease or condition in a subject, method for modulating pi3k enzymatic activity
|
CA2831590A1
(en)
|
2011-03-28 |
2012-10-04 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
CA2843324A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
JP6092849B2
(en)
|
2011-05-04 |
2017-03-08 |
バランス セラピューティックス, インコーポレイテッドBalance Therapeutics, Inc. |
Pentylenetetrazole derivatives
|
CN103827113A
(en)
|
2011-06-23 |
2014-05-28 |
Map药物公司 |
Novel fluoroergoline analogs
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
RU2014111823A
(en)
|
2011-08-29 |
2015-10-10 |
Инфинити Фармасьютикалз, Инк. |
HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
|
EP2755985B1
(en)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
AR088441A1
(en)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
AR089650A1
(en)
|
2011-10-14 |
2014-09-10 |
Idenix Pharmaceuticals Inc |
PHOSPHATES 3,5-REPLACED CYCLES OF PURINE NUCLEOTIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
|
WO2013056070A2
(en)
|
2011-10-14 |
2013-04-18 |
Ambit Biosciences Corporation |
Heterocyclic compounds and methods of use thereof
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
US8946420B2
(en)
|
2011-12-21 |
2015-02-03 |
Map Pharmaceuticals, Inc. |
Neuromodulatory compounds
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
US8916555B2
(en)
|
2012-03-16 |
2014-12-23 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
PE20150132A1
(en)
|
2012-05-22 |
2015-02-14 |
Idenix Pharmaceuticals Inc |
D-AMINO ACID COMPOUNDS FOR HEPATIC DISEASE
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
EP2877465A4
(en)
|
2012-07-25 |
2016-05-11 |
Sarcode Bioscience Inc |
Lfa-1 inhibitor and polymorph thereof
|
PL2882441T3
(en)
|
2012-08-09 |
2020-09-21 |
Celgene Corporation |
Treatment of immune-related and inflammatory diseases
|
UA114521C2
(en)
|
2012-08-09 |
2017-06-26 |
Селджин Корпорейшн |
Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
TW201414721A
(en)
|
2012-09-07 |
2014-04-16 |
Axikin Pharmaceuticals Inc |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
AP2015008384A0
(en)
|
2012-10-08 |
2015-04-30 |
Univ Montpellier Ct Nat De La Rech Scient |
2'-Chloro nucleoside analogs for hcv infection
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
PT2914296T
(en)
|
2012-11-01 |
2018-10-30 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
CA2890177A1
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014085633A1
(en)
|
2012-11-30 |
2014-06-05 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
EP2934143A4
(en)
|
2012-12-21 |
2016-06-15 |
Map Pharmaceuticals Inc |
Novel methysergide derivatives
|
WO2014110305A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
US9545446B2
(en)
|
2013-02-25 |
2017-01-17 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
KR20160013204A
(en)
|
2013-05-30 |
2016-02-03 |
인피니티 파마슈티칼스, 인코포레이티드 |
Treatment of cancers using pi3 kinase isoform modulators
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
KR20160055170A
(en)
|
2013-08-30 |
2016-05-17 |
암비트 바이오사이언시즈 코포레이션 |
Biaryl acetamide compounds and methods of use thereof
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
BR112016007467B1
(en)
|
2013-10-04 |
2022-09-20 |
Infinity Pharmaceuticals, Inc |
HETEROCYCLIC COMPOUNDS AND USES THEREOF
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3054969B1
(en)
|
2013-10-10 |
2021-03-10 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
WO2015081133A2
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
Nucleotides for the treatment of liver cancer
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
CN113620958A
(en)
|
2014-03-19 |
2021-11-09 |
无限药品股份有限公司 |
Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders
|
CA2943231C
(en)
|
2014-03-20 |
2023-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
US10005765B2
(en)
|
2014-03-20 |
2018-06-26 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
CA2944549A1
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxin useful for the treatment of pain
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
SG11201609256SA
(en)
|
2014-05-12 |
2016-12-29 |
Conatus Pharmaceuticals Inc |
Treatment of the complications of chronic liver disease with caspase inhibitors
|
AU2015265607A1
(en)
|
2014-05-28 |
2016-11-17 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
GEP20197011B
(en)
|
2014-06-19 |
2019-08-12 |
Ariad Pharma Inc |
Heteroaryl compounds for kinase inhibition
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
US20170319548A1
(en)
|
2014-09-12 |
2017-11-09 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
RS60737B1
(en)
|
2014-10-21 |
2020-09-30 |
Ariad Pharma Inc |
Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidine-2,4-diamine
|
US20170354639A1
(en)
|
2014-10-24 |
2017-12-14 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
HUE049801T2
(en)
|
2014-12-23 |
2020-10-28 |
Sma Therapeutics Inc |
3,5-diaminopyrazole kinase inhibitors
|
CA2974117A1
(en)
|
2015-01-20 |
2016-07-28 |
Xoc Pharmaceuticals, Inc. |
Ergoline compounds and uses thereof
|
JP2018502889A
(en)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
Isoergoline compounds and uses thereof
|
JP2016175900A
(en)
*
|
2015-03-18 |
2016-10-06 |
参天製薬株式会社 |
Sustained-release pharmaceutical composition
|
CN108368147A
(en)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
Nucleotide for treating cancer
|
AU2016270984B2
(en)
|
2015-06-03 |
2021-02-25 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
AU2016282790B9
(en)
|
2015-06-23 |
2020-01-30 |
Neurocrine Biosciences, Inc. |
VMAT2 inhibitors for treating neurological diseases or disorders
|
US10328087B2
(en)
|
2015-07-23 |
2019-06-25 |
Therapeuticsmd, Inc. |
Formulations for solubilizing hormones
|
HUE057306T2
(en)
|
2015-08-17 |
2022-04-28 |
Kura Oncology Inc |
Methods of treating cancer patients with farnesyl transferase inhibitors
|
WO2017059385A1
(en)
|
2015-09-30 |
2017-04-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
AU2016343633B2
(en)
|
2015-10-30 |
2021-07-01 |
Neurocrine Biosciences, Inc. |
Valbenazine salts and polymorphs thereof
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
PT3394057T
(en)
|
2015-12-23 |
2022-04-21 |
Neurocrine Biosciences Inc |
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
JP2019500397A
(en)
|
2015-12-31 |
2019-01-10 |
クオナトウス ファーマシューティカルズ,インコーポレイテッド |
Methods of using caspase inhibitors for the treatment of liver disease
|
EP3399980A4
(en)
|
2016-01-08 |
2019-09-04 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
ES2957477T3
(en)
|
2016-01-08 |
2024-01-19 |
Celgene Corp |
Antiproliferative compounds for use in the treatment of leukemia
|
CN108712904B
(en)
|
2016-01-08 |
2022-08-02 |
细胞基因公司 |
Solid forms of 2- (4-chlorophenyl) -N- ((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2, 2-difluoroacetamide and pharmaceutical compositions and uses thereof
|
CN108884130B
(en)
|
2016-01-11 |
2022-09-13 |
博士医疗爱尔兰有限公司 |
Formulations and methods for treating ulcerative colitis
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
US10286077B2
(en)
|
2016-04-01 |
2019-05-14 |
Therapeuticsmd, Inc. |
Steroid hormone compositions in medium chain oils
|
AU2017239645A1
(en)
|
2016-04-01 |
2018-10-18 |
Therapeuticsmd, Inc. |
Steroid hormone pharmaceutical composition
|
CN108884019A
(en)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
Deuterated chloramines ketone derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
WO2017190086A1
(en)
|
2016-04-29 |
2017-11-02 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
CN109310743A
(en)
|
2016-05-16 |
2019-02-05 |
因塔西亚制药公司 |
Glucagon receptor selectivity polypeptide and its application method
|
TWI753910B
(en)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN110072861B
(en)
|
2016-09-07 |
2022-11-11 |
Fgh生物科技公司 |
Disubstituted pyrazoles for the treatment of diseases
|
AU2017326558B2
(en)
|
2016-09-19 |
2022-01-06 |
Mei Pharma, Inc. |
Combination therapy
|
EA201991091A1
(en)
|
2016-11-03 |
2019-11-29 |
|
WAYS OF TREATMENT OF PATIENTS WITH MALIGNANT NEW FORMATIONS USING PHARNESYL TRANSFERASE INHIBITORS
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
US10988442B2
(en)
|
2016-11-09 |
2021-04-27 |
Novomedix, Llc |
Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
EP3548007A4
(en)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
US20200078352A1
(en)
|
2016-12-02 |
2020-03-12 |
Neurocrine Biosciences, Inc. |
Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
|
EP3565580B1
(en)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
|
WO2018140092A1
(en)
|
2017-01-27 |
2018-08-02 |
Obrien Christopher F |
Methods for the administration of certain vmat2 inhibitors
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CN114796218A
(en)
|
2017-02-21 |
2022-07-29 |
库拉肿瘤学公司 |
Methods of treating cancer using farnesyl transferase inhibitors
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
EP3601326A4
(en)
|
2017-03-20 |
2020-12-16 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
WO2018183782A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
CN110831945B
(en)
|
2017-03-29 |
2023-08-08 |
赛特温治疗公司 |
11, 13-modified saxitoxins for the treatment of pain
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(en)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
Pharmaceutical compositions and methods of treating cardiovascular diseases
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
ES2913213T3
(en)
|
2017-05-19 |
2022-06-01 |
Nflection Therapeutics Inc |
Condensed Aniline Heteroaromatic Compounds for the Treatment of Skin Disorders
|
MX2019013561A
(en)
|
2017-05-19 |
2022-02-09 |
Nflection Therapeutics Inc |
Pyrrolopyridine-aniline compounds for treatment of dermal disorders.
|
CA3064274A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
SG11202000894TA
(en)
|
2017-08-07 |
2020-02-27 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
AU2018335259A1
(en)
|
2017-09-21 |
2020-04-09 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
AU2017435893B2
(en)
|
2017-10-10 |
2023-06-29 |
Neurocrine Biosciences, Inc |
Methods for the administration of certain VMAT2 inhibitors
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
TW201929847A
(en)
|
2018-01-10 |
2019-08-01 |
美商克拉治療有限責任公司 |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
WO2019139869A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
WO2019241555A1
(en)
|
2018-06-14 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
US11447497B2
(en)
|
2018-06-29 |
2022-09-20 |
Histogen, Inc. |
(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
AU2019322863A1
(en)
|
2018-08-15 |
2021-03-11 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
EP3860714B1
(en)
|
2018-10-03 |
2023-09-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
SG11202104296TA
(en)
|
2018-11-01 |
2021-05-28 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
CN113645964A
(en)
|
2018-11-20 |
2021-11-12 |
恩福莱克逊治疗有限公司 |
Arylaniline and heteroarylaniline compounds for use in fetal marker therapy
|
MA55144A
(en)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
|
JP7406264B2
(en)
|
2018-11-20 |
2023-12-27 |
エヌフレクション セラピューティクス インコーポレイテッド |
Cyanoaryl-aniline compounds for the treatment of skin disorders
|
EP4233865A3
(en)
|
2018-11-20 |
2023-09-27 |
NFlection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
US20230078755A1
(en)
|
2018-12-19 |
2023-03-16 |
Shy Therapeutics, Llc |
Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
US20220071941A1
(en)
|
2018-12-21 |
2022-03-10 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
CN113874080A
(en)
|
2019-02-06 |
2021-12-31 |
戴斯阿尔法公司 |
IL-17A modulators and uses thereof
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
JP2022524049A
(en)
|
2019-03-07 |
2022-04-27 |
クオナトウス ファーマシューティカルズ,インコーポレイテッド |
Caspase inhibitors and how to use them
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
CA3146159A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
US20220274922A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
EP4003314A4
(en)
|
2019-07-26 |
2023-09-20 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
IL291345B2
(en)
|
2019-09-16 |
2024-04-01 |
Dice Alpha Inc |
Il-17a modulators and uses thereof
|
WO2021059023A1
(en)
|
2019-09-26 |
2021-04-01 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
KR20220091488A
(en)
|
2019-10-01 |
2022-06-30 |
몰레큘러 스킨 테라퓨틱스, 인코포레이티드 |
Benzoxazinone Compounds as KLK5/7 Dual Inhibitors
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
EP4168414A1
(en)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
CA3188924A1
(en)
|
2020-08-14 |
2022-02-17 |
Hassan Pajouhesh |
Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
EP4284377A1
(en)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Methods for the treatment of fibrotic disease
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
BR112023018290A2
(en)
|
2021-03-10 |
2023-12-12 |
Dice Molecules Sv Inc |
ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
TW202327590A
(en)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
Macrocyclic compounds and compositions, and methods of preparing and using the same
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023192817A1
(en)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
TW202342070A
(en)
|
2022-03-30 |
2023-11-01 |
美商拜奧馬林製藥公司 |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
US20230331693A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|